UPDATED Mar 10, 2024
Highly cyclical companies in construction-related industries with a strong future outlook.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
---|---|---|---|---|---|---|---|---|---|---|
NEUNeuren Pharmaceuticals | AU$19.95 | 1.4% | 119.5% | AU$2.5b | AU$26.74 | PE16.2x | E5.2% | n/a | ||
ACRAcrux | AU$0.051 | -10.5% | -22.7% | AU$14.8m | n/a | PS1.3x | E115.3% | 0% | ||
TLXTelix Pharmaceuticals | AU$11.70 | -1.3% | 74.1% | AU$3.8b | AU$14.47 | PE727.4x | E37.9% | n/a | ||
IMMImmutep | AU$0.41 | 13.9% | 54.7% | AU$487.4m | AU$1.30 | PS124x | E65.6% | n/a | ||
MVPMedical Developments International | AU$0.72 | -7.7% | -41.2% | AU$62.1m | AU$2.32 | PS1.9x | E78.9% | 0% | ||
MYXMayne Pharma Group | AU$6.98 | 2.5% | 83.2% | AU$567.1m | AU$7.04 | PS1.8x | E110.2% | n/a | ||
KZAKazia Therapeutics | AU$0.08 | -27.3% | -17.5% | AU$18.9m | n/a | PS34068.4x | E49.6% | n/a | ||
MSBMesoblast | AU$0.32 | 6.8% | -67.2% | AU$319.7m | n/a | PS28.3x | E65.5% | n/a | ||
IMUImugene | AU$0.11 | -4.3% | -15.4% | AU$805.0m | n/a | PS53.6x | E62.0% | n/a |